Literature DB >> 2894791

Continuous narcotic infusion with patient-controlled analgesia for chronic cancer pain in outpatients.

I G Kerr1, M Sone, C Deangelis, N Iscoe, R MacKenzie, T Schueller.   

Abstract

STUDY
OBJECTIVE: To determine the feasibility and safety of outpatient continuous narcotic infusions with additional bolus capabilities (patient-controlled analgesia) in patients with cancer pain.
DESIGN: A single arm (non-randomized) series.
SETTING: Outpatient with contact by telephone and through outpatient clinic. PATIENTS: Consecutive series of 18 patients with poorly controlled cancer pain or significant side effects from regular administration of various narcotics.
INTERVENTIONS: Patients taught and supervised to use portable pump capable of delivering a continuous narcotic infusion with bolus capabilities.
MEASUREMENTS AND MAIN RESULTS: All patients had improvement in pain control as judged by the use of a linear analogue scale. Side effects and safety profile were highly acceptable. Narcotics used and maximum doses were meperidine, 50 mg/h; morphine, 80 mg/hr; and hydromorphone, 60 mg/hr. Infusion duration ranged from 7 to 225 days (mean, 54 days).
CONCLUSIONS: Continuous narcotic infusions using a programmable portable pump with bolus capabilities is a safe and reliable method of delivering narcotics to outpatients.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2894791     DOI: 10.7326/0003-4819-108-4-554

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  14 in total

Review 1.  Breakthrough pain in cancer patients: new therapeutic approaches to an old challenge.

Authors:  S K Reddy; P Nguyen
Journal:  Curr Rev Pain       Date:  2000

2.  A computer-based system for controlling plasma opioid concentration according to patient need for analgesia.

Authors:  H F Hill; R C Jacobson; B A Coda; A M Mackie
Journal:  Clin Pharmacokinet       Date:  1991-04       Impact factor: 6.447

3.  Subcutaneous or intravenous opioid administration by patient-controlled analgesia in cancer pain: a systematic literature review.

Authors:  Lisa Nijland; Pia Schmidt; Michael Frosch; Julia Wager; Bettina Hübner-Möhler; Ross Drake; Boris Zernikow
Journal:  Support Care Cancer       Date:  2018-07-28       Impact factor: 3.603

4.  Safety profile of intravenous patient-controlled analgesia for breakthrough pain in cancer patients: a case series study.

Authors:  Angela Maria Sousa; José de Santana Neto; Gabriel M N Guimaraes; Giovana M Cascudo; José Osvaldo B Neto; Hazem A Ashmawi
Journal:  Support Care Cancer       Date:  2013-11-21       Impact factor: 3.603

5.  [Patient-controlled analgesia (PCA) in outpatients with cancer pain. Analysis of 1,692 treatment days].

Authors:  C Schiessl; J Bidmon; R Sittl; N Griessinger; J Schüttler
Journal:  Schmerz       Date:  2007-02       Impact factor: 1.107

6.  Chronic fatigue syndrome: have flawed assumptions been derived from treatment-based studies?

Authors:  J A Richman; J A Flaherty; K M Rospenda
Journal:  Am J Public Health       Date:  1994-02       Impact factor: 9.308

7.  Subcutaneous narcotic infusions for cancer pain: treatment outcome and guidelines for use.

Authors:  D E Moulin; N G Johnson; N Murray-Parsons; M F Geoghegan; V A Goodwin; M A Chester
Journal:  CMAJ       Date:  1992-03-15       Impact factor: 8.262

Review 8.  Patient-controlled analgesia. Pharmacokinetic and therapeutic considerations.

Authors:  H F Hill; L E Mather
Journal:  Clin Pharmacokinet       Date:  1993-02       Impact factor: 6.447

9.  [Pharmacotherapy of cancer pain : 2. Use of opioids.].

Authors:  N I Cherny; R K Portenoy; M Raber; M Zenz
Journal:  Schmerz       Date:  1995-01       Impact factor: 1.107

10.  [Patient-controlled analgesia with subcutaneous opoids for out-patients with severe tumour pain.].

Authors:  H Goeke; M Herbst
Journal:  Schmerz       Date:  1993-03       Impact factor: 1.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.